Allergy Therapeutics plc has disclosed a Form 8.5 (EPT/RI) from Panmure Gordon (UK) Limited, an exempt principal trader with recognized intermediary status. The form provides key information regarding dealings in Allergy Therapeutics' securities. The date of dealing was August 25, 2023. The form indicates that there were purchases and sales of the company's 0.1p ordinary shares, with a total of 23,076 shares sold at a price of 0.026 per unit.

The form does not disclose any cash-settled derivative transactions or stock-settled derivative transactions, including options. It also states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities.

The contact person for this disclosure is Freddie Wooding, and the date of disclosure is August 29, 2023. The form emphasizes that public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service, and the Panel's Market Surveillance Unit is available for consultation regarding the Code's dealing disclosure requirements.